University of Texas's MD Anderson Cancer Center: Dual Checkpoint Blockade Promising as Pre-Surgical Approach for Certain Patients With Localized Bladder Cancer
October 13, 2020
October 13, 2020
HOUSTON, Texas, Oct. 13 (TNSJou) -- The University of Texas's MD Anderson Cancer Center issued the following news release:
Neoadjuvant, or pre-surgical, combination treatment with the immune checkpoint inhibitors tremelimumab (anti-CTLA-4) and durvalumab (anti-PD-1) was well-tolerated and showed early signs of activity in certain patients with localized bladder cancer who do not have standard treatment options available, according to a Phase I clinical trial conducted by The Un . . .
Neoadjuvant, or pre-surgical, combination treatment with the immune checkpoint inhibitors tremelimumab (anti-CTLA-4) and durvalumab (anti-PD-1) was well-tolerated and showed early signs of activity in certain patients with localized bladder cancer who do not have standard treatment options available, according to a Phase I clinical trial conducted by The Un . . .